BackXenon Pharmaceuticals Overview

Xenon Pharmaceuticals Operating Income

Latest operating income for XENE: $-470M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

-$120.07M
↓ 24.63% YoY

As of Sep 30, 2026

Annual Operating Income (TTM)

-$465.32M
↓ 36.54% YoY

Trailing 12 months ending Sep 30, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Xenon Pharmaceuticals (XENE) FAQ

Xenon Pharmaceuticals's operating income stands at $-470M as of September 2026. That compares with $-340M in the prior-year period — down 36.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Xenon Pharmaceuticals reported $-470M in operating income versus $-340M a year earlier — a 36.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-340M in the prior-year period — down 36.5% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Xenon Pharmaceuticals's operating income evolved across reporting periods, while the comparison chart places XENE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. Xenon Pharmaceuticals's reading of $-470M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.